ClinicalTrials.gg
CompletedNCT02459158Updated Jul 5, 2017

A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

A Phase 1 interventional study of ME1100 inhalation solution and ME1100 inhalation solution in Pneumonia, Bacterial, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-05.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Pneumonia, Bacterial with a site in United States — none open to participants now, 2 under way, none of them phase 3. Pneumonia, Bacterial · United States.

Enrollment
35th of 44
25 · median 120
Started
2015
with 2 others
Phase 1
4 of 50
none open now
Registered
27th of 50
by date

Among the 50 studies in Pneumonia, Bacterial with a site in United States, this one is the 35th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2015, is one of 4 in phase 1, and was the 27th registered.

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

Browse Pneumonia, Bacterial studies →

Open to participants now

None of the 50 studies in Pneumonia, Bacterial with a site in United States is open now. The open studies under Pneumonia, Bacterial, anywhere →

Who these studies take

Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies in Pneumonia, Bacterial with a site in United States as a file.
02

Study summary

This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP). The secondary objective of this study is to assess the safety and tolerability of ME1100 for the treatment of subjects with MVBP to assess the safety and tolerability of ME1100.

03

Conditions studied

  • Pneumonia, Bacterial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria in order to be eligible for the study:

  1. Is a hospitalized male or female, ≥ 18 years of age at the Screening Visit;
  2. Is on mechanical ventilation;
  3. Has a known or suspected mechanically ventilated bacterial pneumonia with at least 1 of the following:

    • Fever (> 38.5゚C or > 101.3゚F);
    • Hypothermia (≤ 35.0゚C or ≤ 95.0゚F);
    • Leukopenia (≤ 4500 cells/mm3);
    • Leukocytosis (≤ 10000 cells/mm3);
    • White blood cell count with left shift defined as > 15% immature polymorphonuclear leukocytes (bands) on peripheral blood smear; or
    • Procalcitonin > 0.25 µg/mL;

    Plus at least 2 of the following:

    • Respiratory failure requiring mechanical ventilation;
    • New onset of expectorated or suctioned purulent sputum production or respiratory secretions, or a change in the character of sputum;
    • Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation;
    • Dyspnea, tachypnea, or signs of respiratory distress as evidenced by an increase in respiratory support or oxygen requirement, particularly if any or all of these are progressive in nature; or
    • Hypoxemia by pulse oximetry or arterial blood gas requiring an increase in supplemental oxygen;
  4. Has a chest X-ray with a new consolidation consistent with pneumonia or significant worsening of previous findings consistent with pneumonia; and
  5. Has an Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥ 8 and ≤ 30 at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following exclusion criteria will not be enrolled in the study:

  1. Has a requirement of inhaled non-study antibiotic;
  2. Has been treated with any inhaled antibiotic (including inhaled aminoglycosides) within 72 hours of study entry;
  3. Has renal insufficiency at Screening as evidenced by an estimated \<50 mL/min based on the Cockcroft-Gault formula;
  4. Is at risk of rapidly fatal illness and death within the next 72 hours;
  5. Is a pregnant or nursing female. Females of must have a serum pregnancy test prior to enrollment. If results of the serum pregnancy test are not available prior to the Day 1 Treatment Visit, the patients may be enrolled on the basis of a negative urine pregnancy test; however, the results of the serum pregnancy test must still be obtained. If either test is positive, the patients must be excluded;
  6. Has myasthenia gravis, parkinsonism, or any other progressive neuromuscular disorder;
  7. Has a history of epilepsy or known seizure disorder;
  8. Has a history of sensorineural hearing loss resulting from any therapy known as ototoxic (eg, aminoglycosides, cisplatin, loop diuretics, or quinine);
  9. Has received any medication in the last 30 days (or 5 half-lives of the investigational medication, whichever is longer) prior to the Screening Visit; or
  10. Has known to ME1100, aminoglycosides, or any of the specified Best Available Therapy agents or their .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Low dose of ME1100

    Drug: ME1100 inhalation solution

  • Experimental
    High dose of ME1100

    Drug: ME1100 inhalation solution

Interventions

  • DrugArbekacinStudies of ArbekacinArbekacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system

    Also known as: Arbekacin inhalation solution

  • DrugArbekacinStudies of ArbekacinArbekacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system

    Also known as: Arbekacin inhalation solution

06

What researchers measure

Primary outcomes

  1. Arbekacin concentrations in respiratory fluids collected via bronchoalveolar lavage (BAL) for epithelial lining fluid (ELF)

    Time frame: Day 3

  2. Plasma arbekacin concentrations

    Time frame: Day 1 to Day 5

  3. Urinary elimination of arbekacin

    Time frame: Day 2

  4. Arbekacin concentrations in tracheal aspirate

    Time frame: Day 2

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Screening through 14 days after the end of treatment

07

Study locations

14 sites
  • Martinez, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Jacksonville, Florida, United States
  • Hazard, Kentucky, United States
  • Worcester, Massachusetts, United States
  • Kalamazoo, Michigan, United States
  • Buffalo, New York, United States
  • Greensboro, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Lima, Ohio, United States
  • Toledo, Ohio, United States
  • Houston, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2015
First posted
Jun 1, 2015
Start
Sep 2015
Primary completionActual
Mar 22, 2017
CompletionActual
Mar 22, 2017
Last update
Jul 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02459158
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Jun 1, 2015
Start date
Sep 2015
Primary completion
Mar 22, 2017
Completion
Mar 22, 2017
Last update
Jul 5, 2017

Study contacts

Meiji Study Director
study director · Meiji Seika Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arbekacin

Start the discussion